Inclusion Criteria:

          -  Patients with non-metastatic, node positive, HER2 negative breast cancer, confirmed by
             pathology report, who are in remission and defined as having no evidence of disease
             (NED); HER2 negative is defined as

               -  0-1+ HER2 expression by immunohistochemistry (IHC) OR

               -  Fluorescence in situ hybridization (FISH) negative OR

               -  HER2 2+ and FISH negative

          -  Patients must be at least 28 days post cytotoxic chemotherapy, radiotherapy,
             monoclonal antibody and/or other biologic therapy, prior to enrollment; patients on
             bisphosphonates, denosumab, and/or endocrine therapy and may continue throughout
             duration of study

          -  Patients must be at least 28 days post systemic steroids prior to enrollment

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score
             of =< 2

          -  White blood cell (WBC) >= 3000/mm^3

          -  Hemoglobin (Hgb) >= 10 g/dl

          -  Lymphocyte count >= 800/mm^3

          -  Platelet count >= 75,000/mm^3

          -  Serum creatinine =< 2.0 mg/dl or creatinine clearance > 60 ml/min

          -  Total bilirubin =< 1.5 mg/dl

          -  Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) =< 2
             times upper limit of normal (ULN)

          -  Glycosylated hemoglobin measurement (HbA1c) < 5.7%

          -  Patients must have recovered from major infections and/or surgical procedures, and in
             the opinion of the investigator, not have any significant active concurrent medical
             illnesses precluding protocol treatment

          -  Patients who are having sex that can lead to pregnancy must agree to use adequate
             contraception (hormonal, barrier method of birth control, or abstinence) for the
             duration of study participation; should a woman become pregnant while participating in
             the study, she should inform her study doctor immediately and will not receive any
             more study treatment

          -  Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal
             (LLN) for institution performing based on results from the multi-gated acquisition
             (MUGA) or echocardiogram (ECHO) done at baseline

          -  Willing to not undergo any elective surgical procedure with general anesthesia or
             conscious sedation through the 1 month post-vaccination visit

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with any of the following cardiac conditions:

               -  Symptomatic restrictive cardiomyopathy

               -  Dilated cardiomyopathy

               -  Unstable angina within 4 months prior to enrollment

               -  New York Heart Association functional class III-IV heart failure on active
                  treatment

               -  Symptomatic pericardial effusion

          -  Patients may not be receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to WOKVAC

          -  Patients with any contraindication or known hypersensitivity to receiving
             sargramostatin (recombinant human granulocyte macrophage colony stimulating factor
             [rhuGM-CSF]) or other yeast based products

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with this vaccine

          -  History of diabetes

          -  Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C

          -  History of autoimmunity that has not been controlled with treatment in the last 12
             months